| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
|
Husereau, Don
|
|
2013
|
31 |
5 |
p. 361-367
|
artikel
|
| 2 |
Golimumab for the Treatment of Ankylosing Spondylitis: A NICE Single Technology Appraisal
|
Armstrong, Nigel
|
|
2013
|
31 |
5 |
p. 415-425
|
artikel
|
| 3 |
How Much Should the NHS Pay for a QALY?
|
Haycox, Alan
|
|
2013
|
31 |
5 |
p. 357-359
|
artikel
|
| 4 |
Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States
|
Simpson, Kit N.
|
|
|
31 |
5 |
p. 427-444
|
artikel
|
| 5 |
Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States
|
Simpson, Kit N.
|
|
2013
|
31 |
5 |
p. 427-444
|
artikel
|
| 6 |
Optimal Global Value of Information Trials: Better Aligning Manufacturer and Decision Maker Interests and Enabling Feasible Risk Sharing
|
Eckermann, Simon
|
|
2013
|
31 |
5 |
p. 393-401
|
artikel
|
| 7 |
Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.
|
Baal, Pieter van
|
|
2013
|
31 |
5 |
p. 369-373
|
artikel
|
| 8 |
Review of the Cost Effectiveness of Pharmacogenetic-Guided Treatment of Hypercholesterolaemia
|
Sorich, Michael J.
|
|
2013
|
31 |
5 |
p. 377-391
|
artikel
|
| 9 |
Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma
|
Greenhalgh, Janette
|
|
2013
|
31 |
5 |
p. 403-413
|
artikel
|
| 10 |
The Authors’ Reply to van Baal et al.: “Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.”
|
Grima, Daniel T.
|
|
2013
|
31 |
5 |
p. 375-376
|
artikel
|
| 11 |
The Determinants of Cost-Effectiveness Potential: An Historical Perspective on Lipid-Lowering Therapies
|
Refoios Camejo, Rodrigo
|
|
2013
|
31 |
5 |
p. 445-454
|
artikel
|
Tijdschrift beschrijving